Ethosuximide occupies a singular clinical niche: it is the drug of choice for pure childhood absence epilepsy (CAE) when generalized tonic-clonic seizures (GTCSs) are absent, offering efficacy equivalent to valproate for absence suppression with a substantially more favorable adverse effect profile. Its mechanism is unusually selective, and understanding why it works for absence but not for other seizure types is essential for rational use.
Ethosuximide acts by blocking T-type voltage-gated calcium channels (VGCCs) in thalamic relay neurons and reticular thalamic neurons. T-type calcium channels (also called low-voltage-activated calcium channels) are distinguished from the high-voltage-activated L-, N-, and P/Q-type channels by their activation at membrane potentials close to the resting potential, typically around –65 to –70 mV. This low threshold means they can be activated by relatively small depolarizations – precisely the kind of rhythmic, oscillatory depolarizations that occur in thalamic neurons during absence seizures. The thalamo-cortical circuit generates the 3-Hz spike-and-wave discharge characteristic of absence epilepsy through a cyclical interplay between thalamic relay neurons and reticular thalamic neurons. T-type channels in reticular thalamic neurons generate the low-threshold calcium burst that sustains this oscillation. By blocking these channels, ethosuximide interrupts the oscillatory circuit without broadly suppressing neuronal excitability, which explains both its efficacy in absence and its lack of utility in other seizure types.1
The pharmacokinetics of ethosuximide are straightforward. It is well absorbed orally with bioavailability approaching 100%. Peak plasma concentrations occur approximately 3–7 hours after oral dosing. It is distributed throughout total body water with a volume of distribution of approximately 0.7 L/kg. Protein binding is low (less than 10%), which means the free fraction is high and therapeutic drug monitoring (TDM) of total drug concentrations reliably reflects active drug exposure. Ethosuximide is metabolized primarily by hepatic cytochrome P450 (CYP) 3A4 to inactive hydroxylated metabolites; roughly 20% is excreted unchanged in the urine. The elimination half-life is approximately 40–60 hours in adults and 30–40 hours in children, allowing once-daily or twice-daily dosing. Therapeutic plasma concentrations are typically 40–100 mcg/mL. There are no clinically significant pharmacokinetic drug interactions attributable to ethosuximide itself, as it does not meaningfully inhibit or induce CYP enzymes.2
The Childhood Absence Epilepsy (CAE) study by Glauser and colleagues, published in 2010, established the modern hierarchy of absence epilepsy treatment. In this landmark randomized trial comparing ethosuximide, valproate, and lamotrigine in children with newly diagnosed CAE, ethosuximide and valproate produced significantly higher seizure-freedom rates at 16 weeks (53% and 58%, respectively) than lamotrigine (29%). However, the neuropsychological assessment component of the trial revealed that valproate-treated children showed significantly worse attentional function compared to ethosuximide-treated children, without corresponding differences in seizure control. This finding elevated ethosuximide to preferred first-line status for CAE in the absence of generalized tonic-clonic seizures. The attentional impairment seen with valproate in this pediatric cohort is consistent with the broader adverse cognitive profile of valproate and reinforces the importance of agent-specific adverse effect consideration when selecting therapy for a condition that is itself often associated with attentional difficulties.3
Ethosuximide's adverse effect profile is generally mild. The most common adverse effects are gastrointestinal – nausea, vomiting, anorexia, and abdominal discomfort – which are dose-related and often manageable by taking the drug with food or dividing the daily dose. Central nervous system (CNS) adverse effects include drowsiness, dizziness, headache, and hiccups; the hiccups are an occasionally persistent and bothersome adverse effect unique to this drug. Behavioral adverse effects including irritability, agitation, and, rarely, psychosis have been reported, particularly in patients with underlying psychiatric vulnerability. Rare but serious idiosyncratic reactions include systemic lupus erythematosus (SLE) and aplastic anemia; complete blood counts and urinalysis should be obtained periodically during long-term use, though the frequency of these reactions is low. Ethosuximide has no established teratogenic profile and is not a first-line treatment choice during pregnancy because CAE virtually always remits before or during the reproductive years, but it has lower teratogenic concern than valproate if use during pregnancy were necessary.4
Ethosuximide is preferred over valproate for childhood absence epilepsy (CAE) when generalized tonic-clonic seizures (GTCSs) are absent. Both agents produce equivalent absence suppression, but valproate causes worse attentional function in children (CAE trial, Glauser 2010) and carries greater systemic toxicity risk (hepatotoxicity, weight gain, teratogenicity). Valproate is preferred when GTCSs are present alongside absence seizures, because ethosuximide has no efficacy against tonic-clonic seizures and valproate covers both components. Lamotrigine is a second-line option for absence when both ethosuximide and valproate are not tolerated or are contraindicated, but has substantially lower seizure-freedom rates than either first-line agent in CAE. In juvenile myoclonic epilepsy (JME), ethosuximide is not effective and should not be used.
Brivaracetam (BRV) is the closest structural analog to levetiracetam (LEV) in clinical use, but it differs in ways that matter clinically. Its approximately 15–30-fold higher binding affinity for synaptic vesicle glycoprotein 2A (SV2A) relative to levetiracetam, combined with a more favorable psychiatric adverse effect profile, makes it a meaningful therapeutic alternative rather than merely a me-too compound.
Like levetiracetam, brivaracetam binds selectively to synaptic vesicle glycoprotein 2A (SV2A), a transmembrane protein present on synaptic vesicle membranes throughout the brain. SV2A is thought to regulate the priming and release-readiness of synaptic vesicles, and its modulation by SV2A ligands reduces the probability of vesicle fusion and neurotransmitter release during high-frequency neuronal firing. The precise molecular mechanism by which SV2A binding translates into reduced seizure susceptibility remains under investigation, but it appears to selectively dampen pathologically hyperactive neuronal circuits without broadly suppressing normal synaptic transmission. Brivaracetam's binding affinity for SV2A is approximately 15–30 times higher than that of levetiracetam in radioligand binding assays, and it also has a markedly higher brain penetration rate, reaching peak brain concentrations faster than levetiracetam after equivalent systemic dosing. These pharmacodynamic differences may underlie its apparent efficacy at lower doses relative to the SV2A site occupancy achieved by standard levetiracetam dosing.5
Brivaracetam is rapidly and completely absorbed orally, with bioavailability exceeding 95% and peak plasma concentrations reached within 1 hour. Food does not meaningfully affect absorption. Protein binding is approximately 17%, which is low. Brivaracetam is metabolized primarily by hydrolysis (via amidase enzymes) to an inactive carboxylic acid metabolite, with a minor contribution from CYP2C19-mediated hydroxylation. The elimination half-life is approximately 7–8 hours, necessitating twice-daily dosing. Unlike levetiracetam, which is renally eliminated largely unchanged, brivaracetam undergoes hepatic metabolism, and its metabolites are then excreted renally. Dose adjustment is recommended in moderate to severe hepatic impairment. Brivaracetam is a weak inhibitor of epoxide hydrolase and can modestly increase carbamazepine-10,11-epoxide levels, a metabolite of carbamazepine (CBZ) that contributes to CBZ toxicity; this interaction warrants clinical awareness when the two drugs are used together. Rifampin and other potent CYP inducers reduce brivaracetam exposure and may require dose increase.6
The most clinically relevant advantage of brivaracetam over levetiracetam is its more favorable psychiatric adverse effect profile. Levetiracetam's irritability, agitation, hostility, and behavioral disturbance, occurring in 10–15% of patients, represent one of the primary reasons for drug discontinuation in clinical practice. Randomized controlled trials comparing brivaracetam to placebo in adults with drug-resistant focal epilepsy have consistently demonstrated that psychiatric adverse effects – particularly irritability and behavioral symptoms – occur significantly less frequently with brivaracetam than with levetiracetam in head-to-head comparisons. This difference is hypothesized to reflect brivaracetam's lack of meaningful activity at the alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor and N-methyl-D-aspartate (NMDA) receptor systems that levetiracetam modestly influences, though this mechanistic explanation remains partly speculative. Brivaracetam has an IV formulation bioequivalent to oral dosing, making it suitable for patients unable to take oral medications.7
SV2A binding affinity: brivaracetam (BRV) is 15–30× higher than levetiracetam (LEV). Brain penetration: BRV reaches peak brain concentrations faster. Psychiatric AEs: significantly less irritability and behavioral disturbance with BRV. Half-life: BRV approximately 7–8 h (twice daily) vs LEV 6–8 h (twice daily) – similar. Renal elimination: LEV is predominantly renally cleared; BRV requires dose adjustment in hepatic (not renal) impairment. Drug interactions: BRV weakly inhibits epoxide hydrolase – monitor CBZ epoxide levels. Current indication: adjunctive therapy for focal onset seizures in adults and adolescents ≥4 years. Switching from LEV to BRV: clinically feasible; ratio approximately 1:10 (mg LEV to mg BRV), though individual titration is required.
Cenobamate is a tetrazole-containing compound approved in 2019 for focal onset seizures in adults. Its dual mechanism – combining enhanced sodium channel slow inactivation with positive allosteric modulation of GABA-A receptors at a site distinct from the benzodiazepine binding site – and its unusually high seizure-freedom rates in drug-resistant focal epilepsy make it one of the most pharmacologically distinctive agents approved in recent years.
Cenobamate exerts its anti-seizure effects through two distinct molecular mechanisms acting in parallel. First, it enhances the slow inactivation of voltage-gated sodium (Na+) channels, a mechanism it shares with lacosamide but produces more potently. Slow inactivation refers to a prolonged conformational state of the sodium channel that occurs with sustained or repetitive depolarization; enhancement of this state reduces the availability of sodium channels during high-frequency firing, selectively suppressing repetitive, seizure-like neuronal activity while preserving normal low-frequency synaptic transmission. This is distinct from the fast inactivation enhanced by phenytoin and carbamazepine, and it provides a mechanistically complementary action that may explain cenobamate's efficacy in patients already failing other sodium channel agents. Second, cenobamate acts as a positive allosteric modulator (PAM) of GABA-A receptors at a binding site that is distinct from the benzodiazepine binding site (the benzodiazepine site is located at the interface of alpha and gamma subunits; cenobamate appears to act at a site involving alpha and beta subunits). This non-benzodiazepine GABA-A PAM activity enhances chloride conductance and inhibitory tone through a mechanism that does not show cross-tolerance with classic benzodiazepines.8
The efficacy data for cenobamate in drug-resistant focal epilepsy are striking. In the pivotal C017 study, cenobamate at doses of 200 mg/day and 400 mg/day reduced median seizure frequency by 55% and 55%, respectively, versus 24% for placebo. More remarkable were the seizure-freedom rates: approximately 21% of patients receiving 200 mg/day achieved complete seizure freedom during the 12-week maintenance period, compared with 1% for placebo. These seizure-freedom rates are substantially higher than those seen with any previously approved anti-seizure drug (ASD) for drug-resistant focal epilepsy, where rates of 3–8% are typical. This level of efficacy has generated considerable clinical interest in cenobamate as a later-line agent in refractory focal epilepsy, though it must be balanced against its interaction burden and the DRESS (drug reaction with eosinophilia and systemic symptoms) risk associated with rapid titration.9
The most serious safety concern with cenobamate is DRESS (drug reaction with eosinophilia and systemic symptoms), a potentially life-threatening hypersensitivity syndrome. In the early clinical program, four cases of DRESS occurred when cenobamate was titrated rapidly (over 1–2 weeks). Subsequent implementation of a slow titration schedule – starting at 12.5 mg/day for 2 weeks, then 25 mg/day for 2 weeks, then increasing by 25 mg every 2 weeks – eliminated DRESS in subsequent trials with over 1,900 patients. Slow titration is therefore mandatory and non-negotiable; clinical settings must be aware that rapid titration, even in urgent circumstances, is prohibited. The DRESS syndrome, if it occurs, presents with fever, rash, facial edema, lymphadenopathy, eosinophilia, and organ involvement (hepatitis, nephritis); it requires immediate drug discontinuation and specialist management. Other adverse effects include somnolence, dizziness, headache, and diplopia, which are dose-related and manageable with slow titration.9
Cenobamate carries a significant drug interaction burden that requires careful management. It is both an inducer and an inhibitor of CYP2C19, depending on dose: at lower doses it acts primarily as a weak inhibitor of CYP2C19, while at higher doses (above approximately 200 mg/day) induction becomes the dominant effect. It also induces CYP3A4 at therapeutic doses. The practical consequences are substantial: phenytoin levels increase markedly (CYP2C19 inhibition reduces phenytoin metabolism), potentially causing phenytoin toxicity; carbamazepine (CBZ) levels may decrease due to CYP3A4 induction; and midazolam and other CYP3A4-substrate benzodiazepines have reduced exposure. Clobazam levels are increased by cenobamate via CYP2C19 inhibition, increasing the risk of sedation and respiratory depression from the active metabolite N-desmethylclobazam. Review of all co-medications for CYP2C19 and CYP3A4 interactions is mandatory before initiating cenobamate. The U.S. label recommends reducing phenytoin or phenobarbital doses by 50% when cenobamate is added.10
DRESS (drug reaction with eosinophilia and systemic symptoms) occurred in 4 cases with rapid cenobamate titration and was eliminated by the following mandatory slow titration schedule: 12.5 mg/day × 2 weeks → 25 mg/day × 2 weeks → then increase by 25 mg every 2 weeks as tolerated to target dose (200–400 mg/day). This slow schedule is non-negotiable. Monitor for fever, rash, lymphadenopathy, or eosinophilia – discontinue immediately if DRESS is suspected. Also reduce phenytoin or phenobarbital dose by approximately 50% at cenobamate initiation due to CYP2C19 inhibition. Check all co-medications for CYP2C19 and CYP3A4 interactions before prescribing.
Perampanel is the only approved non-competitive antagonist of the alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) subtype of ionotropic glutamate receptors. Its mechanism is unique among anti-seizure drugs, it is the only agent with once-daily dosing driven by its pharmacokinetics rather than a modified-release formulation, and its psychiatric adverse effects – including aggression – require specific counseling and patient selection considerations.
Glutamate is the primary excitatory neurotransmitter in the central nervous system (CNS), and its AMPA receptors mediate the fast component of excitatory postsynaptic potentials that initiate and propagate seizure activity. Perampanel binds to a site on the AMPA receptor that is distinct from the glutamate binding site (the agonist-orthosteric site) – this non-competitive or allosteric antagonism means that perampanel's effect is not overcome by high glutamate concentrations, unlike competitive antagonists whose binding can be displaced by the endogenous agonist. By blocking AMPA receptors, perampanel reduces fast excitatory neurotransmission without affecting NMDA (N-methyl-D-aspartate) receptors, which mediate a slower, more sustained component of glutamatergic transmission and are associated with more severe cognitive and dissociative adverse effects when blocked. This selectivity is pharmacologically advantageous and explains perampanel's relatively tolerable cognitive profile despite its glutamate antagonism.11
Perampanel is well absorbed orally (bioavailability approximately 100%) and is highly protein-bound (approximately 95%). Its most clinically distinctive pharmacokinetic feature is its exceptionally long elimination half-life of approximately 70–110 hours, which supports once-daily dosing. The long half-life also means that steady-state concentrations are not achieved for 2–3 weeks after a dose change, and that drug accumulation and withdrawal effects evolve slowly. Perampanel is metabolized primarily by cytochrome P450 (CYP) 3A4 to inactive oxidative and glucuronide conjugate metabolites. Strong CYP3A4 inducers such as carbamazepine, phenytoin, and oxcarbazepine reduce perampanel plasma concentrations substantially – by approximately 50–67% – and therefore require higher perampanel doses to achieve therapeutic effect. Conversely, CYP3A4 inhibitors increase perampanel exposure. Perampanel is approved for adjunctive treatment of focal onset seizures in patients 4 years and older, and for adjunctive treatment of primary generalized tonic-clonic seizures in patients 12 years and older.12
The psychiatric and behavioral adverse effects of perampanel are its most clinically significant safety concern. Irritability, aggression, anger, and hostility occur in a dose-dependent manner, with rates of serious psychiatric adverse effects including homicidal ideation reported in post-marketing surveillance, though these are rare. In randomized controlled trials, psychiatric adverse effects occurred in approximately 12% of perampanel-treated patients at doses of 8–12 mg/day, compared with approximately 6% for placebo. The FDA label carries a boxed warning for serious psychiatric and behavioral reactions, and clinicians are advised to monitor patients closely, particularly at higher doses and in patients with a history of psychiatric illness. Dose reduction typically ameliorates behavioral symptoms. Other common adverse effects include dizziness, somnolence, fatigue, and ataxia, which are also dose-related. The long half-life of perampanel means that if adverse effects develop, they persist for days to weeks after dose reduction or discontinuation. Patients and caregivers should be counseled explicitly about the risk of behavioral change before prescribing, and the drug should be initiated at 2 mg/day at bedtime with slow upward titration.13
Perampanel carries an FDA boxed warning for serious psychiatric and behavioral reactions, including aggression, hostility, irritability, anger, and homicidal ideation. These are dose-dependent and occur more frequently above 8 mg/day. Counsel patients and caregivers before initiating. Use with particular caution in patients with pre-existing psychiatric illness, substance use disorders, or behavioral instability. Consider perampanel a second- or third-line agent rather than initial therapy in patients with significant psychiatric history. Monitor at each dose increase. If behavioral changes occur, reduce dose before discontinuing entirely, as the long half-life (70–110 hours) means rapid discontinuation is not needed for symptom management.
Gabapentin and pregabalin are structurally related to gamma-aminobutyric acid (GABA) but do not act on GABA receptors. Their mechanism – binding to the alpha-2-delta (α2δ) auxiliary subunit of voltage-gated calcium channels – is unique among anti-seizure drugs, though their clinical role in epilepsy is narrow. Their much broader use in neuropathic pain, fibromyalgia, and anxiety makes them among the most prescribed drugs in any specialty.
Despite their names suggesting GABAergic activity, neither gabapentin nor pregabalin directly activates GABA receptors or affects GABA synthesis or degradation. Their primary mechanism of action involves high-affinity binding to the alpha-2-delta (α2δ) auxiliary subunit of voltage-gated calcium channels, particularly the α2δ-1 and α2δ-2 isoforms. The α2δ subunit is a regulatory protein that is trafficked to the cell membrane and modulates the density and activity of the principal pore-forming (alpha-1) subunit of voltage-gated calcium channels. By binding to α2δ, gabapentin and pregabalin reduce calcium channel trafficking to the presynaptic membrane, reducing calcium influx at the presynaptic terminal during action potentials and consequently reducing neurotransmitter release. This mechanism selectively dampens neurotransmitter release from hyperactive neurons, since calcium influx during high-frequency firing generates greater α2δ subunit upregulation (as occurs in injured or sensitized neural tissue), providing relative selectivity for pathologically overactive circuits. The α2δ-1 subunit is upregulated in dorsal root ganglion neurons and spinal cord neurons after peripheral nerve injury, which explains the analgesic efficacy of these agents in neuropathic pain states.14
As anti-seizure drugs (ASDs), both gabapentin and pregabalin have documented efficacy exclusively as adjunctive therapy for focal onset seizures, with no evidence of efficacy in generalized seizure types including absence, myoclonic, or primary generalized tonic-clonic seizures. In clinical practice, their anti-seizure role is secondary to their analgesic and anxiolytic uses, and they are rarely initiated primarily for epilepsy in current practice because more efficacious and better-characterized ASDs are available. Gabapentin's pharmacokinetics are complicated by saturable absorption: it is absorbed via a transporter-mediated mechanism in the small intestine that becomes saturated at higher doses, resulting in non-linear, dose-dependent bioavailability that ranges from approximately 60% at low doses to less than 35% at high doses. This non-linear absorption means dose increases do not produce proportional increases in plasma concentration and complicates dose titration. Gabapentin is not protein-bound, not metabolized, and eliminated entirely by renal excretion unchanged; dose adjustment for renal impairment is mandatory and substantial. Pregabalin has more predictable linear pharmacokinetics with bioavailability exceeding 90% across its full dose range, also with renal elimination unchanged and no hepatic metabolism; its more reliable pharmacokinetics make it preferable to gabapentin in most clinical contexts where either might be used.15
Adverse effects of gabapentin and pregabalin are primarily CNS-related: somnolence, dizziness, ataxia, peripheral edema, and weight gain. These effects are dose-related and are the main tolerability limitations in clinical use. Both agents have low drug interaction potential due to absence of protein binding and lack of hepatic metabolism, making them particularly useful in patients on complex multi-drug regimens. However, both drugs have emerged as drugs with significant abuse and misuse potential, particularly in patients with opioid use disorder, where concurrent use produces enhanced sedation and euphoria; pregabalin has schedule V controlled substance status in the United States. Respiratory depression can occur when these agents are combined with opioids, benzodiazepines, or other CNS depressants, and this risk has been highlighted in regulatory warnings. Pregabalin is approved for neuropathic pain associated with diabetic peripheral neuropathy, post-herpetic neuralgia, fibromyalgia, and spinal cord injury pain, as well as generalized anxiety disorder (in Europe) and as adjunctive therapy for focal seizures. Abrupt discontinuation of either agent after prolonged use can cause a withdrawal syndrome including anxiety, insomnia, nausea, and sweating, and in severe cases seizures; gradual taper is recommended.15
Absorption: gabapentin has saturable, non-linear absorption (bioavailability 35–60% depending on dose); pregabalin has linear absorption (>90% across dose range) – pregabalin is more predictable. Dosing: gabapentin requires three-times-daily dosing for consistent levels; pregabalin is twice daily. Renal adjustment: both require dose reduction with renal impairment (creatinine clearance <60 mL/min); neither is hepatically metabolized. Potency: pregabalin is approximately 2–6× more potent per mg than gabapentin. Controlled status: pregabalin is schedule V in the U.S.; gabapentin is schedule V in some states only. Anti-seizure role: both are adjuncts for focal onset seizures only – neither is effective in generalized epilepsy.
Ethosuximide: first-line for pure childhood absence epilepsy (CAE) without tonic-clonic seizures. No utility outside absence syndromes.
Brivaracetam: adjunct for focal seizures; preferred over levetiracetam (LEV) when LEV psychiatric adverse effects are limiting or when faster brain penetration is desired. Modest interaction with CBZ epoxide.
Cenobamate: reserve for drug-resistant focal epilepsy; highest seizure-freedom rates of any newer ASD. Mandatory slow titration (DRESS risk). Significant CYP interactions – review all co-medications.
Perampanel: adjunct for focal and primary GTCS; unique AMPA antagonism; once-daily dosing. Boxed warning for aggression and behavioral change – careful patient selection required.
Gabapentin/Pregabalin: adjuncts for focal seizures only; primarily used for neuropathic pain, fibromyalgia, anxiety. Abuse potential; non-linear absorption (gabapentin); renal dose adjustment required for both.
Coulter DA, Huguenard JR, Prince DA. Characterization of ethosuximide reduction of low-threshold calcium current in thalamic neurons. Ann Neurol. 1989;25(6):582–593.
doi:10.1002/ana.410250610Patsalos PN, Berry DJ, Bourgeois BF, et al. Antiepileptic drugs: best practice guidelines for therapeutic drug monitoring. Epilepsia. 2008;49(7):1239–1276.
doi:10.1111/j.1528-1167.2008.01561.xGlauser TA, Cnaan A, Shinnar S, et al. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy. N Engl J Med. 2010;362(9):790–799.
doi:10.1056/NEJMoa0902014Glauser TA, Cnaan A, Shinnar S, et al. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy: initial monotherapy outcomes at 12 months. Epilepsia. 2013;54(1):141–155.
doi:10.1111/epi.12028Nicolas JM, Hannestad J, Holden D, et al. Brivaracetam, a selective high-affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of action. Epilepsia. 2016;57(2):201–209.
doi:10.1111/epi.13267Moseley BD, Chanteux H, Nicolas JM, Laloyaux C, Gidal B, Stockis A. A review of the drug-drug interactions of the antiepileptic drug brivaracetam. Epilepsy Res. 2020;163:106327.
doi:10.1016/j.eplepsyres.2020.106327Stockis A, Hartstra J, Mollet M, Hadi S. Bioavailability and bioequivalence comparison of brivaracetam 10, 50, 75, and 100 mg tablets and 100 mg intravenous bolus. Epilepsia. 2016;57(8):1288–1293.
doi:10.1111/epi.13433Nakamura M, Cho JH, Shin H, Jang IS. Effects of cenobamate (YKP3089), a newly developed antiepileptic drug, on voltage-gated sodium channels in rat hippocampal CA3 neurons. Eur J Pharmacol. 2019;855:175–182.
doi:10.1016/j.ejphar.2019.05.007Krauss GL, Klein P, Brandt C, et al. Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trial. Lancet Neurol. 2020;19(1):38–48.
doi:10.1016/S1474-4422(19)30399-0Guery D, Rheims S. Clinical review of cenobamate as adjunctive therapy for the treatment of uncontrolled focal-onset seizures in adults. Drug Des Devel Ther. 2021;15:3591–3600.
doi:10.2147/DDDT.S287014Hanada T, Hashizume Y, Tokuhara N, et al. Perampanel: a novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsy. Epilepsia. 2011;52(7):1331–1340.
doi:10.1111/j.1528-1167.2011.03109.xFrench JA, Krauss GL, Biton V, et al. Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304. Neurology. 2012;79(6):589–596.
doi:10.1212/WNL.0b013e3182635735Ettinger AB, LoPresti A, Yang H, Williams B, Zhou S, Fain R, Laurenza A. Psychiatric and behavioral adverse events in randomized clinical studies of the noncompetitive AMPA receptor antagonist perampanel. Epilepsia. 2015;56(8):1252–1263.
doi:10.1111/epi.13054Dolphin AC. Voltage-gated calcium channels and their auxiliary subunits: physiology and pathophysiology and pharmacology. J Physiol. 2016;594(19):5369–5390.
doi:10.1113/JP272262Bockbrader HN, Wesche D, Miller R, Chapel S, Janiczek N, Burger P. A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin. Clin Pharmacokinet. 2010;49(10):661–669.
doi:10.2165/11536200-000000000-00000